A new standard for medical marijuana, established by Edmonton researchers, warns family doctors that the risks may outweigh the benefits for the vast majority of patients.
The standard, published Thursday in the Canadian Family Physician journal, suggests the benefits of medical cannabis may be overstated, and research on it’s medicinal properties is sorely lacking.
Canadian doctors should think twice before recommending the drug, said Dr. Mike Allan, who led the research team.
“While enthusiasm for medical marijuana is very strong among some people, good quality research has not caught up,” Allan, the director of evidence-based medicine at the University of Alberta, said in a statement.
The guideline was based on a review of clinical trials involving medical cannabis.
The document will be distributed to 30,000 physicians across Canada, and is intended as a new protocol for doctors to use when deciding whether or not to prescribe marijuana.
‘In general we’re talking about one study, and often very poorly done.’
– Dr. Mike Allan
Thousands of Canadians are already prescribed medical marijuana, and that number is expected to rise after marijuana is legalized this summer.
Family doctors face increasing pressure from patients asking for medicinal pot. The study authors suggest there is little data for physicians to rely on before making that decision.
Guideline authors found that, in most cases, the number of randomized studies involving medical cannabis was extremely small.
In the rare instances where research did exist, the studies were narrow in scope or poorly executed, said Allan.
” In general, we’re talking about one study, and often very poorly done,” Allan said in a statement.
” For example, there are no studies for the treatment of depression.”.
There was also only one study on anxiety and it was unscientific, said Allan. In that trial, half of the 24 patients involved received a single dose of cannabis derivative and scored their anxiety doing a simulated presentation.
” This is hardly adequate to determine if lifelong treatment of conditions like general anxiety disorders is reasonable,” said Allan.
Researchers concluded there is adequate evidence for the use of medical cannabinoids to treat a handful of specific medical conditions, including nerve pain, palliative cancer pain, muscle tightness associated with multiple sclerosis or spinal cord injury, and nausea from chemotherapy.
Even in those specific cases, the benefits were found to be generally minor, said Allan.
” Medical cannabinoids should normally only be considered in the small handful of conditions with adequate evidence, and only after a patient has tried a number of standard therapies,” Allan said in a statement.
” Given the inconsistent nature of medical marijuana dosing and possible risks of smoking, we also recommend that pharmaceutical cannabinoids be tried first before smoked medical marijuana.”.
While the researchers found limited evidence supporting the use of medical cannabinoids, the side-effects were consistent and common. Common side effects included dizziness, confusion and sedation.
‘Better research is definitely needed’.
Allan acknowledged the guideline may prove controversial, since the debate over medical marijuana is divisive..
” This guideline may be unsatisfactory for some, particularly those with polarized views regarding medical cannabinoids,” Allan said.
” Better research is definitely needed– randomized control trials that follow a large number of patients for longer periods of time. If we had that, it could change how we approach this issue and help guide our recommendations.”.
The research was overseen by a committee of 10 medical professionals, including doctors, pharmacists, patients and nurses, and was peer-reviewed by 40 others.
Medical colleges have released some general guidelines for primary-care providers and have cautioned physicians against prescribing marijuana.
A trio of advisories prepared by the Alberta College of Family Physicians in 2017 summarized the scientific literature, or lack thereof, that dealt with medicinal marijuana.
Documents released by the colleges of physicians and surgeons in both British Columbia and Alberta cite the absence of reliable evidence to demonstrate the effectiveness of cannabis as medication.